Figure 2From: Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: a case report Examination 3 months after the second injection of bevacizumab (dose 1.25mg/0.05ml) revealed inferior scarring and significant reduction of corneal new vessels in number and size (arrows). Back to article page